【诚意药业:原料药盐酸多巴酚丁胺获上市批准】诚意药业公告,公司近日收到国家药监局核准签发的关于原料药盐酸多巴酚丁胺的《化学原料药上市申请批准通知书》。该原料药用于心血管疾病治疗,属于β受体激动剂,通过刺激心脏β1受体,增强心肌收缩力,同时扩张周围血管,降低心脏负荷。目前国内生产厂商有浙江瑞新药业和上海紫源制药等。公司未能从公开渠道获得该产品的销售情况。公司在该原料药研发项目上累计研发投入约519.82万元。此次获得上市批准将丰富公司产品线,有助于拓展业务领域,但不会对当前业绩产生重大影响。

金融界
29 Apr
诚意药业公告,公司近日收到国家药监局核准签发的关于原料药盐酸多巴酚丁胺的《化学原料药上市申请批准通知书》。该原料药用于心血管疾病治疗,属于β受体激动剂,通过刺激心脏β1受体,增强心肌收缩力,同时扩张周围血管,降低心脏负荷。目前国内生产厂商有浙江瑞新药业和上海紫源制药等。公司未能从公开渠道获得该产品的销售情况。公司在该原料药研发项目上累计研发投入约519.82万元。此次获得上市批准将丰富公司产品线,有助于拓展业务领域,但不会对当前业绩产生重大影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10